{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T13:51:35Z","timestamp":1768312295864,"version":"3.49.0"},"reference-count":26,"publisher":"Impact Journals, LLC","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging"],"published-print":{"date-parts":[[2021,8,31]]},"DOI":"10.18632\/aging.203409","type":"journal-article","created":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T06:32:41Z","timestamp":1629441161000},"page":"20246-20257","source":"Crossref","is-referenced-by-count":4,"title":["Identification of effective natural PIK3CA H1047R inhibitors by computational study"],"prefix":"10.18632","volume":"13","author":[{"given":"Naimeng","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Breast Surgery, The First Hospital of Jilin University, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinhui","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, First People\u2019s Hospital of Xinxiang, Xinxiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Tangdu Hospital, The Fourth Military Medical University, Xi\u2019an, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaye","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Hematology, Honghui Hospital, Xi\u2019an Jiao Tong University, Xi\u2019an, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haoqun","family":"Xie","sequence":"additional","affiliation":[{"name":"Clinical College, Jilin University, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Guo","sequence":"additional","affiliation":[{"name":"Clinical College, Jilin University, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[{"name":"Clinical College, Jilin University, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaojing","family":"Dou","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The First Hospital of Jilin University, Changchun, China"},{"name":"Clinical College, Jilin University, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The First Hospital of Jilin University, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The First Hospital of Jilin University, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2021,8,20]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","article-title":"Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies.","volume":"3","author":"Zhang","year":"2019","journal-title":"Cancer Cell"},{"key":"2","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ccell.2018.11.016","article-title":"Tinagl1 Suppresses Triple-Negative Breast Cancer Progression and Metastasis by Simultaneously Inhibiting Integrin\/FAK and EGFR Signaling.","volume":"3","author":"Celi\u00e0-Terrassa","year":"2019","journal-title":"Cancer Cell"},{"key":"3","doi-asserted-by":"publisher","first-page":"916","DOI":"10.3390\/cancers12040916","article-title":"The Landscape of Targeted Therapies in TNBC.","volume":"1","author":"Cristofanilli","year":"2020","journal-title":"Cancers (Basel)"},{"key":"4","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1158\/1055-9965.EPI-17-0627","article-title":"Differences in Breast Cancer Survival by Molecular Subtypes in the United States.","volume":"2","author":"Andridge","year":"2018","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13058-020-01284-9","article-title":"Frequency and spectrum of PIK3CA somatic mutations in breast cancer.","volume":"2","author":"Galv\u00e1n","year":"2020","journal-title":"Breast Cancer Res"},{"key":"6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ctrv.2016.03.004","article-title":"New insights on PI3K\/AKT pathway alterations and clinical outcomes in breast cancer.","volume":"4","author":"Lipkowitz","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"7","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1093\/annonc\/mdz133","article-title":"Targeting the PI3-kinase pathway in triple-negative breast cancer.","volume":"3","author":"Turner","year":"2019","journal-title":"Ann Oncol"},{"key":"8","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41422-020-0375-9","article-title":"Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial.","volume":"3","author":"Kaklamani","year":"2021","journal-title":"Cell Res"},{"key":"9","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13058-019-1154-8","article-title":"Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and\/or PTEN loss\/PTEN mutation.","volume":"2","author":"Piha-Paul","year":"2019","journal-title":"Breast Cancer Res"},{"key":"10","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1002\/1878-0261.12540","article-title":"PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study.","volume":"1","author":"Lianidou","year":"2019","journal-title":"Mol Oncol"},{"key":"11","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/nature14669","article-title":"PIK3CA(H1047R) induces multipotency and multi-lineage mammary tumours.","volume":"52","author":"Bentires-Alj","year":"2015","journal-title":"Nature"},{"key":"12","doi-asserted-by":"publisher","first-page":"689","DOI":"10.4143\/crt.2019.497","article-title":"PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane-Based Neoadjuvant Chemotherapy.","volume":"5","author":"Denkert","year":"2020","journal-title":"Cancer Res Treat"},{"key":"13","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.canlet.2018.11.038","article-title":"Phosphatidyl inositol 3-kinase (PI3K)-mTOR inhibitor PKI-402 inhibits breast cancer induced osteolysis.","volume":"44","author":"Yao","year":"2019","journal-title":"Cancer Lett"},{"key":"14","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1158\/1535-7163.MCT-09-0954","article-title":"Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor.","volume":"9","author":"Gibbons","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"15","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/jrr\/rrz102","article-title":"Wortmannin, a specific inhibitor of phosphatidylinositol-3-kinase, induces accumulation of DNA double-strand breaks.","volume":"6","author":"Kudo","year":"2020","journal-title":"J Radiat Res"},{"key":"16","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/bs.apcsb.2015.09.008","article-title":"Investigating the Inhibitory Effect of Wortmannin in the Hotspot Mutation at Codon 1047 of PIK3CA Kinase Domain: A Molecular Docking and Molecular Dynamics Approach.","volume":"10","author":"Doss","year":"2016","journal-title":"Adv Protein Chem Struct Biol"},{"key":"17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2174\/187152012798764697","article-title":"Natural products: promising resources for cancer drug discovery.","volume":"1","author":"Mandal","year":"2012","journal-title":"Anticancer Agents Med Chem"},{"key":"18","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1530\/ERC-18-0523","article-title":"Prolactin modulates TNBC aggressive phenotype limiting tumorigenesis.","volume":"2","author":"Ali","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2174\/156800908783497140","article-title":"Deregulation of the Akt pathway in human cancer.","volume":"8","author":"Maehara","year":"2008","journal-title":"Curr Cancer Drug Targets"},{"key":"20","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1186\/s12885-018-4811-x","article-title":"Detection of PIK3\/AKT pathway in Moroccan population with triple negative breast cancer.","volume":"1","author":"Fekkak","year":"2018","journal-title":"BMC Cancer"},{"key":"21","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nrm2882","article-title":"The emerging mechanisms of isoform-specific PI3K signalling.","volume":"1","author":"Bilanges","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"key":"22","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1126\/science.1096502","article-title":"High frequency of mutations of the PIK3CA gene in human cancers.","volume":"30","author":"Kinzler","year":"2004","journal-title":"Science"},{"key":"23","doi-asserted-by":"publisher","first-page":"e23342","DOI":"10.1097\/md.0000000000023342","article-title":"Computational study on natural compounds inhibitor of c-Myc.","volume":"9","author":"Zhao","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"24","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.18632\/aging.103986","article-title":"Effective natural inhibitors targeting poly ADP-ribose polymerase by computational study.","volume":"1","author":"Wang","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"25","doi-asserted-by":"publisher","first-page":"8523","DOI":"10.18632\/aging.103155","article-title":"Computational study of novel natural inhibitors targeting aminopeptidase N(CD13).","volume":"1","author":"Liu","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"26","doi-asserted-by":"publisher","first-page":"9738","DOI":"10.18632\/aging.102422","article-title":"Selected by gene co-expression network and molecular docking analyses, ENMD-2076 is highly effective in glioblastoma-bearing rats.","volume":"1","author":"Zhao","year":"2019","journal-title":"Aging (Albany NY)"}],"container-title":["Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.203409","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T16:10:49Z","timestamp":1630944649000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.203409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,20]]},"references-count":26,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2021,8,31]]}},"alternative-id":["203409","34415239"],"URL":"https:\/\/doi.org\/10.18632\/aging.203409","relation":{},"ISSN":["1945-4589"],"issn-type":[{"value":"1945-4589","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,20]]}}}